Skip to main content

Secondary Prevention clinical trials at UC Health
1 in progress, 0 open to eligible people

  • Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

    Sorry, in progress, not accepting new patients

    This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.

    at UC Davis

Last updated: